Debiopharm, an independent biopharmaceutical company based in Switzerland whose mission is to develop tomorrow’s reference treatments to cure cancer and infectious diseases, announced today the signing of a partnership with WhiteLab Genomics (WLG), a biotechnology company based in Paris and Boston, specializing in artificial intelligence (AI) applied to R&D in genomic medicine.
This collaboration aims to achieve two main objectives. The first is to identify cancer-specific receptors that are overexpressed and localized on the surface of cancer cells. The second is to find lead candidates capable of binding to these receptors. Once identified, these agents will be attached to the surface of lipid nanoparticles (LNPs), to improve active tissue targeting.
NPLs have become the gold standard for drug delivery, with the potential to transform oncology care, particularly in genomic medicine, due to their high delivery efficiency. One of the challenges posed by NPLs is their tendency to accumulate in non-target organs, such as the liver, limiting their delivery to the intended site. To maximize the potential of NPLs, WLG is deploying an AI-powered platform to explore innovative in silico approaches to improve the targeted delivery capabilities of NPLs, creating new opportunities for therapeutic applications.
As a major investor in WLG, Debiopharm has consistently supported the company’s innovative approaches and cutting-edge solutions through its Debiopharm Innovation Fund. This collaboration provides a substantial opportunity to validate the potential of WLG’s AI platform and strengthen the ongoing relationship between the two companies.
“WhiteLab’s innovative AI platform represents a significant advancement in the field of targeted cancer therapies. By improving the specificity and delivery of lipid nanoparticles, we aim to provide more effective treatments for patients suffering from hormonal cancers,” said David Del Bourgo, CEO and co-founder of WhiteLab Genomics. “Our collaboration with a leading player such as Debiopharm continues to demonstrate our focus on developing cutting-edge solutions that have the potential to revolutionize cancer treatments.”
“As a drug development company, we understand the challenges of this field and therefore recognize the added value of AI-based platforms, such as WhiteLab Genomics, applied to the early stages of drug R&D. We look forward to fully exploiting the potential of AI-based solutions to develop drugs, mitigate asset risks, minimize toxicity risks and ensure that we bring the most effective and personalized medicines to patients,” said Betrand Ducrey, CEO of Debiopharm.
Source: WhiteLab Genomics / Debiopharm
Related News :